The following video is part of our "Motley Fool Conversations" series, in which Brendan Byrnes, industrials editor and analyst, and David Williamson, health-care editor and analyst, discuss topics around the investing world.

In today's edition, they discuss the two performers in health care for 2011. Both companies have exciting hepatitis C drug candidates catching the attention of Big Pharma. Gilead purchased Pharmasset for $11 billion, a 59% premuim over the company's all-time high.

There's a race among major drugmakers to obtain the most effective next-gen combo drug treatment to eliminate hep-C. Investors are looking for more M&A, as shares of Inhibtex and Achillion have been bid up recently.

Looking for our prediction for 2012? Check out The Motley Fool's brand new report, "The Motley Fool's Top Stock for 2012." It highlights a company that is revolutionizing commerce in Latin America. You can get instant access to the name of this company by clicking here -- it's free.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.